RESEARCH AGREEMENT NO. LLCT-41718Research Agreement • May 31st, 2007 • International Stem Cell CORP • Pharmaceutical preparations • California
This agreement (“AGREEMENT”) is entered into this 2nd day of January 2007, by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, on behalf of its Irvine campus (“UNIVERSITY”) through its employee Dr. Hans Keirstead of the Reeve-Irvine Research Center (“INVESTIGATOR”) and LifeLine Cell Technology LLC, with offices at 157 Surfview Drive, Pacific Palisades, CA 90272 (“SPONSOR”). UNIVERSITY and SPONSOR shall be collectively referred to as the Parties and agree as follows:
SPONSORED RESEARCH AGREEMENTSponsored Research Agreement • May 31st, 2007 • International Stem Cell CORP • Pharmaceutical preparations • Georgia
THIS SPONSORED RESEARCH AGREEMENT (“Agreement”) is made and entered into this 1st day of December, 2006 (hereinafter “Effective Date”) by and between Lifeline Cell Technology, Inc., with offices located at 3355 Lenox Road NE, Suite 415, Atlanta, GA 30326 (hereinafter referred to as “Sponsor”) and Emory University, with offices located at 1784 N. Decatur Road., Suite 510, Atlanta, Georgia 30322 (hereinafter referred to as “Emory”). “Parties” mean Sponsor and Emory and “Party” means Sponsor or Emory.
Re: Consulting Agreement between Kenneth C. Aldrich, William B. Adams and Pacgen Cell Co. [Lifeline Cell Technology]Consulting Agreement • May 31st, 2007 • International Stem Cell CORP • Pharmaceutical preparations
At the International Stem Cell Corporation Board of Director’s meeting on November 17, 2006, we discussed the management fees owed to Mr. Adams and Aldrich. Up to June 1, 2006, Lifeline Cell Technology, LLC was accruing $10,000 per month in fees. From June 1, 2006 to November 1, 2006 the amount was increased to $20,000 per month. Effective November 1, 2006 both Mr. Aldrich and Adams entered into employment agreements with International Stem Cell Corporation. At that time the accrual of additional fees are cancelled. It was further agreed that International Stem Cell Corporation will continue to pay $20,000 per month until the remainder of the obligation is paid in full. Interest will continue to accrue at 10% per annum until paid in full.
